[Transfusions in myelodysplastic syndromes]

Area of Science:

• Hematology
• Transfusion Medicine
• Oncology

Background:

• Myelodysplastic syndromes (MDS) often require packed red blood cell (PRBC) transfusions when erythropoiesis stimulating agents fail.
• Current transfusion triggers, typically 80 g/L hemoglobin, are based on expert consensus, not randomized trials.
• Key risks include red blood cell (RBC) alloimmunization and transfusion-associated circulatory overload (TACO).

Purpose of the Study:

• To highlight the need for randomized controlled trials comparing restrictive versus liberal transfusion policies in MDS.
• To emphasize prophylactic antigen matching for RhCE and K to prevent RBC alloimmunization.
• To discuss strategies for preventing TACO and managing iron overload in transfusion-dependent MDS patients.

Main Methods:

• Literature review and expert consensus synthesis on current transfusion practices in MDS.
• Discussion of evidence-based strategies for risk mitigation, including antigen matching and slow transfusion rates.
• Exploration of iron chelation therapy for long-term transfusion management.

Main Results:

• A randomized controlled trial is necessary to determine optimal transfusion triggers for MDS patients, impacting quality of life and survival.
• Prophylactic antigen matching for RhCE and K is crucial for preventing RBC alloimmunization.
• TACO prevention in high-risk MDS patients involves slow transfusion rates and blood pressure monitoring; iron overload can be managed with chelating agents, with new formulations potentially improving tolerability.

Conclusions:

• Optimizing transfusion strategies in MDS requires further research, particularly randomized trials.
• Careful patient selection, monitoring, and prophylactic measures are essential to minimize transfusion complications.
• Advances in iron chelation therapy may improve long-term management and patient satisfaction in MDS.